Vanda Launches NEREUS First Motion Sickness Drug
Washington, United States | May 1, 2026 Vanda Pharmaceuticals Inc. has announced the U.S. commercial availability of NEREUS™ (tradipitant),...
tradipitant
Advertisement
Vanda Initiates Thetis Trial for GLP-1 Vomiting Prevention
WASHINGTON, April 8, 2026 Vanda Pharmaceuticals Inc. has announced the initiation of the Thetis clinical trial evaluating NEREUS™ (tradipitant)...
FDA Approves NEREUS™, First New Motion Sickness Drug in 40 Years
Washington, D.C. | December 30, 2025 — Vanda Pharmaceuticals Inc. has announced U.S. Food and Drug Administration (FDA) approval...
FDA Advances Tradipitant Review for Motion Sickness Relief
Washington, D.C., November 28, 2025 In a significant regulatory development, Vanda Pharmaceuticals Inc. has announced major progress on tradipitant,...
Advertisement
